PRKG1 and Thrombocytopenia: Recent data from mouse and human platelets revealed that activation of PKA/PKG not only inhibited Thr/Cvx-induced platelet activation but also its pro-coagulant state.13 In the present study, we tested whether or not PKA/PKG activation could inhibit caspase-dependent apoptosis induced by ABT-737 (navitoclax) or thymoquinone (TQ), thereby limiting chemotherapy-induced thrombocytopenia.